Trials / Unknown
UnknownNCT01451580
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer
A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (estimated)
- Sponsor
- TTY Biopharm · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lipo-Dox |
Timeline
- Start date
- 2005-09-01
- First posted
- 2011-10-13
- Last updated
- 2011-10-13
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01451580. Inclusion in this directory is not an endorsement.